Investors relish Sanofi's return to growth and better guidance

31 October 2018
sanofi-paris-big

There were plenty of reasons to be cheerful at Sanofi (Euronext: SAN) on Wednesday as the company presented its third-quarter 2018 results.

Shares in the French drugmaker were up nearly 5% in the early afternoon as markets digested results that showed a return to sales growth and prompted the company to improve its earnings-per-share estimate for the full year.

Using international financial reporting standards (IFRS), net sales for the quarter were 9.32 billion euros ($10.6 billion), an increase of 3.7%, on a reported basis, compared to the same period in 2017.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical